Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: Incidence, risk factors, and prevention

Woods, C. W.;McRill, C.;Plikaytis, B. D.;Rosenstein, N. E.;Mosley, D.;Boyd, D.;England, B.;Perkins, B. A.;Ampel, N. M.;Hajjeh, R. A.

Author address: 

Hajjeh, RA, Ctr Dis Control & Prevent, Mycot Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, MS C-09,1600 Clifton Rd NE, Atlanta, GA 30307 USA


From 1 January 1995 through 31 June 1997, 153 cases of coccidioidomycosis in human immunodeficiency virus (HIV)- infected persons were identified in Arizona (incidence, 41/1000 persons living with AIDS), A case-control study was conducted to evaluate risk factors for coccidioidomycosis in HIV-infected persons. A case was defined as laboratory-confirmed, incident coccidioidomycosis in a person infected with HIV for greater than or equal to 3 months, and each case patient had 3 control patients matched by county, age group, sex, HIV/AIDS status, and CD4 lymphocyte count. Multivariable analysis identified black race and a history of oropharyngeal or esophageal candidiasis to be associated with increased risk of coccidioidomycosis; protease inhibitor therapy was associated with a reduced risk. In persons with previous history of oropharyngeal or esophageal candidiasis, having received an azole drug was associated with a reduced risk (odds ratio, 0.4; 95% confidence interval, 0.2-0.9; P = .04). Physicians may need to consider azole chemoprophylaxis for HIV-infected persons who live in areas of endemicity, have CD4 cell counts

abstract No: 


Full conference title: 

36th Annual Meeting of the Infectious-Diseases-Society-of- America
    • IDSA 36th